Rigel Pharmaceuticals, Inc./$RIGL
1D1W1MYTD1Y5YMAX
Capital at risk
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Ticker
- $RIGL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 173
- Headquarters
- South San Francisco, United States
- Website
- www.rigel.com
RIGL Metrics
BasicAdvanced
$877M
2.86
$16.45
1.17
-
Price and volume
Market cap
$877M
Beta
1.17
52-week high
$52.24
52-week low
$24.95
Average daily volume
257K
Financial strength
Current ratio
1.941
Quick ratio
1.584
Long term debt to equity
0
Total debt to equity
0.094
Interest coverage (TTM)
15.00%
Profitability
EBITDA (TTM)
89.699
Gross margin (TTM)
75.61%
Net profit margin (TTM)
116.30%
Operating margin (TTM)
31.45%
Effective tax rate (TTM)
-276.17%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
14.95%
Return on equity (TTM)
126.90%
Valuation
Price to earnings (TTM)
2.855
Price to revenue (TTM)
3.106
Price to book
2.06
Price to tangible book (TTM)
2.64
Price to free cash flow (TTM)
95.07
Free cash flow yield (TTM)
1.05%
Free cash flow per share (TTM)
0.494
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
202.71%
3-year revenue growth (CAGR)
31.71%
10-year revenue growth (CAGR)
22.92%
3-year earnings per share growth (CAGR)
96.14%
10-year earnings per share growth (CAGR)
11.41%
Bulls say / Bears say
The existing portfolio is still growing and profitable. Q2 net product sales rose 14% year on year to $67.0 million, led by TAVALISSE growth of 18% and REZLIDHIA growth of 27%; Rigel also raised 2026 revenue guidance to $285–295 million and expects positive full-year net income. (PR Newswire)
VEPPANU gives Rigel a new commercial growth engine in breast cancer. It is the first FDA-approved PROTAC for its target patient group, became available in the US in August, and showed better progression-free survival and response measures than fulvestrant in the cited trial data. (Rigel Pharmaceuticals, Exa)
R289 provides a further pipeline catalyst beyond the commercial portfolio. Rigel remains on track to select a Phase 2 dose in the second half of 2026 and release preliminary dose-expansion data by year end in lower-risk myelodysplastic syndrome. (PR Newswire, The Motley Fool)
Growth is uneven across the established products. GAVRETO sales fell 10% year on year in Q2, while TAVALISSE growth benefited from favourable inventory and gross-to-net effects, which may make the reported pace less durable. (PR Newswire, The Motley Fool)
VEPPANU brings substantial execution and funding commitments before its upside is proven. Rigel paid $70 million upfront, may owe up to $320 million in regulatory and commercial milestones, must pay tiered royalties from the mid-teens to mid-20s, and expects to fund up to $40 million of ongoing development work. (Rigel Pharmaceuticals, StockTitan)
The company lost a potential external funding stream when Eli Lilly terminated its global ocadusertib collaboration, returning the rights to Rigel and ending expected future milestone and royalty payments. That leaves Rigel carrying more development and commercial risk across its own portfolio. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
RIGL Financial Performance
Revenues and expenses
RIGL Earnings Performance
Company profitability
Upcoming events
No upcoming events
RIGL News
AllArticlesVideos
Funds containing RIGL
AllUSDGBPEUR
Fund name | Fund size | $RIGL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.